Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
about
Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agentsPalmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Fractional photothermolysis for the treatment of acne scars: a report of 27 Korean patients.Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patientsParadoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn's disease.Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.Psoriasis induced by thalidomide in a patient with multiple myelomaAnti-TNF-Alpha-Induced Psoriasis - An Unusual Paradox.Psoriasis and comorbidities: links and risks.Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-α Inhibitor.Palmoplantar pustulosis with fulminant dystrophic 20-nail psoriasis in a patient receiving adalimumab therapy.Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype.Treatment of severe psoriasis with infliximab.Infliximab-induced acne: a new case and review of published reports.Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.Psoriasiform Eruption and Worsening of Pustulosis Palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with Ustekinumab.More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.Etanercept in the treatment of refractory SAPHO syndrome.Adalimumab induced pulmonary sarcoid reaction.Rheumatic manifestations of skin disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Learning the lessons of antitumour necrosis factor therapy-associated psoriasis.Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Lymphoedema: a paradoxical effect of tumour necrosis factor inhibitors - case report and review of literature.Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases.Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.What's the next best cytokine target in IBD?Assessing the safety of biologic agents in patients with rheumatoid arthritis.The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.A systematic review of SAPHO syndrome and inflammatory bowel disease association.Investigational cytokine-targeted therapies for ulcerative colitis.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Pyoderma gangrenosum: pathogenetic oriented treatment approaches.
P2860
Q22305935-C7FDC478-1DF0-4A4D-8587-4126D871105DQ30251512-C72A68BA-4717-4FA1-AC0D-1D3EAC2FCD86Q30412650-2FB13A27-E91A-40D8-8419-BC3B4EDC988BQ33319813-67BA1C5A-D5B3-4303-A461-B5A0C6BA5CA9Q33735385-DB074183-F150-4FB1-A33A-A631AECBE537Q33736503-CA8724C7-B097-4C2A-94FC-71B9494D3C2CQ33829739-8BB552A8-E54B-4B1D-BFCF-B20A621020A5Q33833466-AE267A66-F22B-4602-922B-8EFE1C87624AQ34336406-F4D920C6-E0CE-43A1-A504-37891EE7F701Q34418506-4507B8E7-C915-4CF6-8E70-DA4CD029D6C0Q34495590-F690130D-7BC6-40F5-89D5-D0460BF81ED8Q34573111-6A17EA40-7B52-4772-B2E2-91E6A7698714Q34620323-BCD31CDA-32BD-4611-B500-BE308D411588Q37018368-E87451F4-3311-4FC7-828D-50BECD994423Q37098135-5B650120-0A4A-44A8-A36D-D4790FF053DBQ37209922-5848D1ED-5C7A-408B-A38B-969C2BBCC567Q37303223-33B066C3-DC61-4861-A31E-9FBF7A804596Q37432268-78DF2DFC-D648-4E4B-91CE-7E5A8FCB8993Q37487110-97C41117-BC59-4B1A-AC58-CD7A3E1EFB97Q37568535-6A2B185D-632E-488A-A5EF-B04ECEC4F96EQ37576496-54F710D0-CA5F-43AC-ADD9-04E7ADAD03CCQ37620086-6CE46B60-486D-4969-8EC7-904481ABBC8EQ37814549-1F8C1579-B7D1-4EE0-A101-7E7D550B8406Q37854163-FE833CE2-15AD-44D0-959B-D0C9BD5399E4Q37859958-349AC7C4-F473-45E5-8A08-4CE85FA47B0EQ37873493-B4301596-28D3-4773-A659-81540A0C1469Q37891744-5011B190-0B78-431D-9997-FA95BA13C3AAQ37909490-2541431B-155E-4FBF-B434-C36FF162163FQ37945313-3C1DFA1A-D5E0-435C-9C50-DE8F9CC9D4F6Q38003092-C52BD8C7-128F-48F9-BF17-71C9CAA01DDAQ38020463-4A010490-D78E-459B-B0EA-BC2A75445AB9Q38024281-F1C87DBF-9B3B-49B3-8925-0CC36E1CB441Q38034394-67FCCFB9-E78C-4814-B034-53C5FB2023A3Q38050938-960B4743-AC6C-4D5A-BFB5-208F5F59661AQ38094618-45DB596D-C721-4C36-8A7E-017FE4655EE3Q38117175-C77E0D80-EE9F-4852-BF3B-FDC3AE5626F7Q38145501-A65A4D2A-2B1B-460D-8018-26D7E3CEA8FEQ38166663-EF1A6A2D-804C-4054-AD7C-EDDE75E83587Q38179468-D4643E73-5AA7-473D-B778-8A67405C73BCQ38217677-90F81A66-6904-4013-9332-6F2B1153C64D
P2860
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor necrosis factor-alpha in ...... a series of six new patients.
@en
Tumor necrosis factor-alpha in ...... a series of six new patients.
@nl
type
label
Tumor necrosis factor-alpha in ...... a series of six new patients.
@en
Tumor necrosis factor-alpha in ...... a series of six new patients.
@nl
prefLabel
Tumor necrosis factor-alpha in ...... a series of six new patients.
@en
Tumor necrosis factor-alpha in ...... a series of six new patients.
@nl
P2093
P1476
Tumor necrosis factor-alpha in ...... a series of six new patients.
@en
P2093
André Koch
Erich Köstler
Gesina Hansel
Jaqueline Schönlebe
P356
10.2165/00128071-200809010-00001
P577
2008-01-01T00:00:00Z
P6179
1001277291